NeuroSigma, Inc. is a Los Angeles-based company that specializes in the development and manufacturing of medical devices for the treatment of neurological disorders. Their flagship product, the Monarch eTNS System, is the first FDA cleared device for treating pediatric Attention Deficit Hyperactivity Disorder (ADHD) as a monotherapy in patients aged 7 to 12 years old who are not currently taking prescription ADHD medications. This innovative device is intended to be used in the home under the supervision of a caregiver during periods of sleep, offering a non-invasive and convenient treatment option for pediatric ADHD.
With a focus on patient safety and efficacy, NeuroSigma has achieved significant milestones, including FDA clearance, HSA approval in Singapore, and the establishment of a subsidiary in Singapore. The company continues to advance its technology, as evidenced by the recent FDA 510 k submission for the second generation Monarch eTNS System. NeuroSigma's commitment to improving the lives of individuals with neurological disorders is further demonstrated through their strategic partnerships, telehealth options, and ongoing clinical trials.
Generated from the website